Literature DB >> 36097175

A blood-based circulating microbial metagenomic panel for early diagnosis and prognosis of oesophageal adenocarcinoma.

Ali H Zaidi1, Muhammad Yogi Pratama2, Ashten N Omstead1, Anastasia Gorbonova1, Rubab Mansoor1, Rachael Melton-Kreft3, Blair A Jobe1, Patrick L Wagner1, Ronan J Kelly4, Ajay Goel5,6.   

Abstract

BACKGROUND: Emerging evidence indicates the potential clinical significance of specific microbial signatures as diagnostic and prognostic biomarkers, in multiple cancers. However, to date, no studies have systematically interrogated circulating metagenome profiling in oesophageal adenocarcinoma (EAC) patients, particularly as novel non-invasive, early detection, surveillance and prognostic classifiers.
METHODS: Metagenome sequencing was performed on 81 serum specimens collected across EAC spectrum, with sequencing reads classified using Bracken and MetaPhlAn3. Followed by the Linear Discriminant Analysis effect size (LEfSe) method to identify microbial profiles between groups. Logistic regression and Kaplan-Meier analyses were used to build classifiers.
RESULTS: A significant loss of alpha and beta diversity was identified in serum specimens from EAC patients. We observed a shift in microbial taxa between each group-at the phylum, genus, and species level-with Lactobacillus sakei as the most prominent species in gastroesophageal reflux (GERD) vs other patient groups. Interestingly, LEfSe analysis identified a complete loss of Lactobacillus (L. Sakei and L. Curvatus), Collinsella stercoris and Bacteroides stercoris but conversely a significant increase in Escherichia coli in patients with EAC. Finally, we developed a metagenome panel that discriminated EAC from GERD patients with an AUC value of 0.89 (95% CI: 0.78-0.95; P < 0.001) and this panel in conjunction with the TNM stage was a robust predictor of overall survival (≥24 months; AUC = 0.84 (95% CI: 0.66-0.92; P = 0.006)).
CONCLUSION: This study firstly describes unique blood-based microbial profiles in patients across EAC carcinogenesis, that are further utilised to establish a novel circulating diagnostic and prognostic metagenomic signature for EAC. TRANSLATIONAL RELEVANCE: Accumulating data indicates the clinical relevance of specific microbial signatures as diagnostic and prognostic biomarkers, in multiple cancers. However, to date, no studies have systematically interrogated circulating metagenome profiling in patients with oesophageal adenocarcinoma (EAC). Herein, we performed metagenome sequencing in serum specimens from EAC patients 81 collected across EAC spectrum and observed a significant loss of alpha and beta diversity, with a shift in microbial taxa between each group-at the phylum, genus, and species level-with Lactobacillus sakei as the most prominent species in gastroesophageal reflux (GERD) vs other patient groups. Interestingly, LEfSe analysis identified a complete loss of Lactobacillus (L. Sakei and L. Curvatus), Collinsella stercoris and Bacteroides stercoris but conversely a significant increase in Escherichia coli in patients with EAC. Finally, we developed a metagenome panel that discriminated EAC from GERD patients with an AUC value of 0.89 and this panel, in conjunction with the TNM stage, was a robust predictor of overall survival. This study for the first time describes unique blood-based microbial profiles in patients across EAC carcinogenesis, that are further utilised to establish a novel circulating diagnostic and prognostic metagenomic signature for EAC.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Year:  2022        PMID: 36097175     DOI: 10.1038/s41416-022-01974-5

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   9.075


  45 in total

1.  Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study.

Authors:  Shivaram Bhat; Helen G Coleman; Fouad Yousef; Brian T Johnston; Damian T McManus; Anna T Gavin; Liam J Murray
Journal:  J Natl Cancer Inst       Date:  2011-06-16       Impact factor: 13.506

Review 2.  Esophageal adenocarcinoma: a review and perspectives on the mechanism of carcinogenesis and chemoprevention.

Authors:  X Chen; C S Yang
Journal:  Carcinogenesis       Date:  2001-08       Impact factor: 4.944

Review 3.  Gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma.

Authors:  John T Chang; David A Katzka
Journal:  Arch Intern Med       Date:  2004-07-26

4.  Alcohol, tobacco, and diet in relation to esophageal cancer: the Shanghai Cohort Study.

Authors:  Yunhua Fan; Jian-Min Yuan; Renwei Wang; Yu-Tang Gao; Mimi C Yu
Journal:  Nutr Cancer       Date:  2008       Impact factor: 2.900

5.  Comparing trends in esophageal adenocarcinoma incidence and lifestyle factors between the United States, Spain, and the Netherlands.

Authors:  S Kroep; I Lansdorp-Vogelaar; J H Rubenstein; V E P P Lemmens; E B van Heijningen; N Aragonés; M van Ballegooijen; J M Inadomi
Journal:  Am J Gastroenterol       Date:  2013-12-17       Impact factor: 10.864

6.  Alcohol, Alcoholic Beverages and Risk of Esophageal Cancer by Histological Type: A Dose-Response Meta-Analysis of Observational Studies.

Authors:  Xiaohui Yu; Jiahao Chen; Wenjie Jiang; Dongfeng Zhang
Journal:  Alcohol Alcohol       Date:  2020-08-14       Impact factor: 2.826

Review 7.  Pathophysiological mechanisms linking obesity and esophageal adenocarcinoma.

Authors:  Leo Alexandre; Elizabeth Long; Ian Lp Beales
Journal:  World J Gastrointest Pathophysiol       Date:  2014-11-15

8.  Signatures within the esophageal microbiome are associated with host genetics, age, and disease.

Authors:  Nandan P Deshpande; Stephen M Riordan; Natalia Castaño-Rodríguez; Marc R Wilkins; Nadeem O Kaakoush
Journal:  Microbiome       Date:  2018-12-17       Impact factor: 14.650

9.  Esophageal Cancer: An Updated Surveillance Epidemiology and End Results Database Analysis.

Authors:  Eric Omar Then; Michell Lopez; Saad Saleem; Vijay Gayam; Tagore Sunkara; Andrea Culliford; Vinaya Gaduputi
Journal:  World J Oncol       Date:  2020-03-29

10.  Risk Factors for Progression of Barrett's Esophagus to High Grade Dysplasia and Esophageal Adenocarcinoma.

Authors:  Swetha Kambhampati; Alan H Tieu; Brandon Luber; Hao Wang; Stephen J Meltzer
Journal:  Sci Rep       Date:  2020-03-17       Impact factor: 4.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.